The Sydney-listed stock dropped as much as 9% in early trading before paring losses to close down 6.5% at A$160.32. The sell-off was triggered by a reported net profit of US$401 million for the six months ending in December—an 80% collapse compared to the previous year. While underlying profit, which excludes one-off items, fell a more modest 6% to US$1.95 billion, the figures fell short of market expectations, primarily due to underperformance in the Behring plasma unit.

Adding to the volatility was the unexpected announcement that Gordon Naylor, a veteran former executive, would replace McKenzie as CEO. Analysts at Jarden noted that the sudden transition heightened investor anxiety over potential downgrades. Despite the turmoil, CSL maintained its full-year guidance, projecting underlying profit growth between 4% and 7%, which implies a total of US$3.35 billion to US$3.44 billion.

Pressure on Plasma Margins

The results exposed vulnerabilities in CSL’s flagship products, specifically immunoglobulin and albumin. According to Macquarie, the Behring division saw revenue fall 10% below forecasts, while gross profits missed targets by 9%. This operational drag was the primary catalyst for the earnings miss, though the company’s dividend remained unchanged at US$1.30 per share.

Market sentiment remains divided on the company's ability to rebound in the second half of the year. While Jefferies maintained a bullish stance, arguing the results were not as dire as the share price reaction suggested, Jarden warned that a lack of investor confidence could keep the stock under pressure. However, some analysts point to a possible recovery in 2026 as new distribution agreements and Medicare funding changes take effect.